Effects of 1α,25-Dihydroxyvitamin D on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Aug 28

PMID 34452094

Citations 3

Authors

Anusha Balla

Yoo-Seong Jeong

Hyo-Jung Kim

Yun-Jong Lee

Suk-Jae Chung

Yoon-Jee Chae

Han-Joo Maeng

Affiliations

Soon will be listed here.

Abstract

In this study, possible changes in the expression of rat organic cationic transporters (rOCTs) and rat multidrug and toxin extrusion proteins (rMATEs) following treatment with 1α,25-dihydroxyvitamin D (1,25(OH)D) were investigated. Rats received intraperitoneal administrations of 1,25(OH)D for four consecutive days, and the tissues of interest were collected. The mRNA expression of rOCT1 in the kidneys was significantly increased in 1,25(OH)D-treated rats compared with the control rats, while the mRNA expressions of rOCT2 and rMATE1 in the kidneys, rOCT1 and N-acetyltransferase-II (NAT-II) in the liver, and rOCT3 in the heart were significantly decreased. Changes in the protein expression of hepatic rOCT1 and renal rOCT2 and rMATE1 were confirmed by western blot analysis. We further evaluated the pharmacokinetics of procainamide (PA) hydrochloride and its major metabolite N-acetyl procainamide (NAPA) in the presence of 1,25(OH)D. When PA hydrochloride was administered intravenously at a dose 10 mg/kg to 1,25(OH)D-treated rats, a significant decrease in renal and/or non-renal clearance of PA and NAPA was observed. A physiological model for the pharmacokinetics of PA and NAPA in rats was useful for linking changes in the transcriptional and translational expressions of rOCTs and rMATE1 transporters to the altered pharmacokinetics of the drugs.

Citing Articles

Formulation and Evaluation of a Self-Microemulsifying Drug Delivery System of Raloxifene with Improved Solubility and Oral Bioavailability.

Ansari M, Vo D, Choi H, Ryu J, Bae Y, Bukhari N Pharmaceutics. 2023; 15(8).

PMID: 37631288 PMC: 10459739. DOI: 10.3390/pharmaceutics15082073.

Synthetic Peucedanocoumarin IV Prevents α-Synuclein Neurotoxicity in an Animal Model of Parkinson's Disease.

Kim H, Maeng H, Kim J, Yoon J, Oh Y, Paek S Int J Mol Sci. 2022; 23(15).

PMID: 35955753 PMC: 9369442. DOI: 10.3390/ijms23158618.

Effects of 1α,25-dihydroxyvitamin D on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats.

Vo D, Nguyen T, Maeng H J Pharm Investig. 2022; 52(3):341-351.

PMID: 35291466 PMC: 8911105. DOI: 10.1007/s40005-022-00563-1.

References

Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y . Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2012; 34(1):45-78. DOI: 10.1002/bdd.1823. View

Atilano-Roque A, Roda G, Fogueri U, Kiser J, Joy M . Effect of Disease Pathologies on Transporter Expression and Function. J Clin Pharmacol. 2016; 56 Suppl 7:S205-21. DOI: 10.1002/jcph.768. View

Tirona R . Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol. 2010; (201):373-402. DOI: 10.1007/978-3-642-14541-4_10. View

Rodgers T, Leahy D, Rowland M . Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005; 94(6):1259-76. DOI: 10.1002/jps.20322. View

Cressman A, Petrovic V, Piquette-Miller M . Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev Clin Pharmacol. 2011; 5(1):69-89. DOI: 10.1586/ecp.11.66. View

Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K . Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007; 74(2):359-71. DOI: 10.1016/j.bcp.2007.04.010. View

Chow E, Durk M, Cummins C, Pang K . 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J Pharmacol Exp Ther. 2011; 337(3):846-59. DOI: 10.1124/jpet.111.179101. View

Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A . The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol. 2009; 5(2):211-23. DOI: 10.1517/17425250802691074. View

Yoon I, Son J, Kim S, Choi M, Maeng H . Effects of 1α,25-Dihydroxyvitamin D3 on Intestinal Absorption and Disposition of Adefovir Dipivoxil and Its Metabolite, Adefovir, in Rats. Biol Pharm Bull. 2015; 38(11):1732-7. DOI: 10.1248/bpb.b15-00356. View

10.

Trujillo T, Nolan P . Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. 2001; 23(6):509-32. DOI: 10.2165/00002018-200023060-00003. View

11.

Moore D, Kato S, Xie W, Mangelsdorf D, Schmidt D, Xiao R . International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D.... Pharmacol Rev. 2006; 58(4):742-59. DOI: 10.1124/pr.58.4.6. View

12.

Dave R, Morris M . Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in rats. J Pharmacokinet Pharmacodyn. 2015; 42(5):497-513. PMC: 4761431. DOI: 10.1007/s10928-015-9441-1. View

13.

Basit A, Radi Z, Vaidya V, Karasu M, Prasad B . Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics. Drug Metab Dispos. 2019; 47(8):802-808. DOI: 10.1124/dmd.119.086579. View

14.

Schneck D, Grove K, DeWitt F, Shiroff R, HAYES Jr A . The quantitative disposition of procainamide and N-acetylprocainamide in the rat. J Pharmacol Exp Ther. 1978; 204(1):219-25. View

15.

Saeki M, Kurose K, Tohkin M, Hasegawa R . Identification of the functional vitamin D response elements in the human MDR1 gene. Biochem Pharmacol. 2008; 76(4):531-42. DOI: 10.1016/j.bcp.2008.05.030. View

16.

Urakami Y, Okuda M, Saito H, Inui K . Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett. 2000; 473(2):173-6. DOI: 10.1016/s0014-5793(00)01525-8. View

17.

Maeng H, Chapy H, Zaman S, Pang K . Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. Eur J Pharm Sci. 2012; 46(3):149-66. DOI: 10.1016/j.ejps.2012.02.018. View

18.

Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang K . Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther. 2009; 330(2):389-402. DOI: 10.1124/jpet.108.149815. View

19.

Takano M, Kato M, Takayama A, Yasuhara M, Inui K, Hori R . Transport of procainamide in a kidney epithelial cell line LLC-PK1. Biochim Biophys Acta. 1992; 1108(2):133-9. DOI: 10.1016/0005-2736(92)90017-g. View

20.

Dreyfuss J, BIGGER Jr J, Cohen A, Schreiber E . Metabolism of procainamide in rhesus monkey and man. Clin Pharmacol Ther. 1972; 13(3):366-71. DOI: 10.1002/cpt1972133366. View